Our research found that TEFT inhibits the TGF‐β signaling pathway, reducing phosphorylation of SMAD2/3 and STAT3, thereby suppressing C1R expression and resulting in weakened EMT and invasive capabilities of GBM. This evidence concerns the gene STAT3 and glioblastoma.